BioSpace News Archive

MacroGenics, Inc., a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, announced that the Company will release its financial results for the fourth quarter of 2022 after the market closes on Wednesday, March 15, 2023.

Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, announced that the United States Food and Drug Administration’s Office of Therapeutic Products has accepted the Company’s Biologics License Application resubmission for remestemcel-L in the treatment of children with steroid-refractory acute graft versus host disease.

Miromatrix Medical Inc. (“Miromatrix”) (Nasdaq: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients’ lives, today announced the pricing of an underwritten public offering of 6,250,000 shares of its common stock at a price to the public of $1.60 per share, before underwriting discounts and commissions.

Biomerica, Inc. announced today the closing of its previously announced underwritten public offering of an aggregate of 3,333,333 shares of its common stock.

Carisma Therapeutics Inc. and Sesen Bio, Inc. (“Sesen Bio”), announced today the closing of their previously announced merger.

Cameras that can scan an entire body in a fraction of a second can give spinal surgeons an accurate assessment of how much range of motion youth with scoliosis have in their torso – a critical piece of information for guiding management of people with the condition, researchers at Hospital for Special Surgery in New York City have found.

Nuvo Pharmaceuticals Inc. d/b/a Miravo Healthcare is pleased to announce that, its shareholders voted in favour of a special resolution to approve the previously announced plan of arrangementpursuant to which, among other things, Searchlight Pharma Inc. will acquire all of the Company shares.

Sensei Biotherapeutics, Inc. today announced that a special committee of the Board of Directors adopted a limited duration stockholder rights agreement (the “Rights Agreement”) to protect stockholder interests and maximize value for all stockholders.

Regeneron Pharmaceuticals, Inc. and Sanofi announced that the U.S. Food and Drug Administration has accepted for review the supplemental Biologics License Application for Dupixent® to treat adults and adolescents aged 12 years and older with chronic spontaneous urticaria that is not adequately controlled with the current standard of care, H1 antihistamine treatment.

AB2 Bio Ltd. announced the completion of enrolment of its ongoing pivotal Phase 3 study of Tadekinig alfa.